Aptadir's €40M seed and the bet on unsilencing a single gene

A company with no drug in human trials just closed the largest early-stage biotech financing in Italian history. The money is real. The molecule has not met a patient.

Aptadir Therapeutics, a preclinical company in Milan, said on 29 September that it raised €40 million — about $45 million — in a seed round led by London's 4BIO Capital. Extend, the national technology-transfer hub run by CDP Venture Capital and financed by Angelini Ventures and Evotec, returned from the pre-seed. Indaco Venture Partners, XGEN Venture, CE-Ventures, Kerna Ventures, Italian Angels for Biotech and Club degli Investitori filled out the syndicate. The company calls it the largest biotech seed in Italy, and one of the largest in Europe this year.

The round is not paying for a drug. It is paying for a method: switching one silenced gene back on, without cutting the genome and without drugging the whole body.

That idea has been circling genetics for two decades. The drugs that proved it can work — azacitidine and decitabine — have been approved since the mid-2000s for myelodysplastic syndromes and leukemia. They block DNA methylation, the chemical tag that keeps a gene quiet. They work. They are also blunt: they hit every dividing cell in the body, and that is why their toxicity has kept them boxed into a corner of oncology.

Aptadir's bet is that the same chemistry can be aimed. Its molecules, which the company calls DNMT-interacting RNAs, or DiRs, are designed to sit on DNMT1 — the enzyme that copies methylation patterns when a cell divides — only at a chosen gene. Stop the writer at one address and the gene reopens. The rest of the genome stays out of it.

The first target silences itself

Fragile X syndrome is the most common inherited cause of intellectual disability and the most common known single-gene cause of autism. It begins with a stutter: a CGG repeat in the FMR1 gene expands past a threshold, the expanded repeat attracts methylation, and FMR1 falls silent. Without the FMRP protein it encodes, brain development goes off course. The CDC estimates that roughly 1 in 7,000 males and 1 in 11,000 females have been diagnosed. No approved therapy restores the protein.

Reactivation, however, is not hypothetical. In 2016, two research groups used CRISPR-Cas9 to delete the expanded repeats in patient-derived cells; FMR1 switched back on and produced the missing protein. That result proved the proximal cause is reversible. Aptadir's route skips the cutting: it tries to remove the methylation that holds the gene down, without editing DNA at all.

The lead candidate, CAP1-FMR1, is designed for exactly that gene. The same platform is being pointed at myelodysplastic syndrome and at tumors where a protective gene has been methylated into silence — a target list that is long, and largely unproven.

What the syndicate is buying

The cap table tells its own story. 4BIO Capital, a London specialist in precision therapies, led. Extend — the hub launched by CDP Venture Capital and jointly funded by Angelini Ventures and Evotec — came back from the pre-seed. CDP's Digital Transition Fund, Indaco, XGEN and CE-Ventures, the corporate arm of Dubai's Crescent Enterprises, joined. The mix matters: a specialist lead, a state-backed technology-transfer vehicle, and a strategic corporate investor are three different kinds of patient capital.

The science carries the same blended signature. The company says the platform rests on work from Beth Israel Deaconess Medical Center, Italy's National Research Council, the Cancer Science Institute of Singapore and City of Hope — academic labs, not a single founder's notebook. Aptadir itself launched only in 2024, with the RNA-inhibitor concept as its founding claim.

We invest with conviction where rigorous biology meets real unmet medical need, and Aptadir's platform does exactly that.— Dima Kuzmin, Managing Partner, 4BIO Capital

The record round in context

CHRONICLE: one gene, twenty years
────────────────────────────────────────────────────────────
  2004 ────── 2016 ──────── 2024 ──────── ◉ 2026
  💊         🧬             🚀            💰
  Azanucleosides   FMR1 reactivated   Aptadir founded   EUR 40M seed
  approved in MDS  in patient cells   on RNA inhibitors for CAP1-FMR1
────────────────────────────────────────────────────────────
Source: FDA approvals; Haenfler et al., 2018; Aptadir Therapeutics, 2026

What has to be true

Patient-derived cells are not patients. The gap between the two is where most genetic medicines have died, and it is wider in the brain than almost anywhere else. A DiR must reach the right cells in the central nervous system, methylate the right address and nowhere else, hold the gene open long enough to matter, and do it reproducibly enough for regulators to accept. None of that is settled. The company itself frames CAP1-FMR1 as preclinical, with no disclosed clinical timeline.

The field's recent history argues for patience. BioAge's Phase 2 disappointment with an aging-adjacent obesity drug is a reminder that a clean mechanism and a compelling story are not the same as an endpoint.

Why the check cleared now

Italy has spent the past few years trying to convert its public research base into companies. Extend exists for that purpose, and Aptadir is one of its first flagship bets. Pair a state transfer hub with a specialist cross-border lead and a corporate strategic, and a preclinical platform can raise a round that a pure venture syndicate might have priced smaller. The €40 million is a statement about the pipeline as much as about the molecule.

As we covered in September, Ultragenyx won the first approval for a Sanfilippo syndrome gene therapy — evidence that regulators will move on rare genetic disease when the data hold. We have also written about the quieter bottleneck: cell and gene therapies win approvals faster than the logistics to deliver them. Aptadir sits on the promising side of that ledger, and squarely inside its unsolved half.

If single-gene demethylation works, the target list runs well past Fragile X — into myelodysplastic syndrome, into silenced tumor suppressors, into imprinting disorders where one copy of a gene is switched off by mistake. If it does not, this is a sharp platform, a sharp story, and another preclinical company that raised too much, too early.

The syndicate is betting it is the first case. The next two years will decide which sentence gets written.